Oral Solubilization Technology: The Business Opportunity
This initiative provides an opportunity for companies to advance
problematic low-solubility compounds that otherwise stall in development, or
require medicinal chemistry intervention. The program consists of three
stages.
Stage 1. Nonconfidential Technical Evaluation
The goal in this stage is to evaluate whether the SDD technology is
appropriate for delivery of your firm's low-solubility compound and to assess
the compound's alignment with Pfizer's portfolio. The information required
to complete the evaluation includes:
- therapeutic target;
- physicochemical properties, such as the compound's structure,
solubility, pKa, and log P; and
- bioavailability, metabolism, and clearance.
Bend Research Inc. may be able to assist with experiments in the absence of
such data.
Stage 2. Feasibility Study
In this stage, a feasibility study will be conducted to establish the in
vivo performance of the SDD formulation. Under a two-way nonanalysis
agreement, Bend Research Inc. - codeveloper of the SDD technology - will
formulate your compound and verify the in vitro performance of the SDD.
Well-established methods are in place to perform these tests rapidly with as
little as 150 mg of bulk drug. The formulated compound will be returned to
your firm, along with the test results and detailed instructions for dosing the
SDD in vivo.
Stage 3. License and Option Negotiations
Following successful feasibility studies, your firm will enter into licensing
discussions with Pfizer.
|
